Smith & New plc Files 6‑K: Executive Share Sales and Cevian Capital’s 14% Holding
Smith & New plc discloses 2026 share‑award vesting, Mr Kashyap’s London trades, and Cevian Capital’s 14% stake—showing full SEC and UK compliance.
2 minutes to read
Dr. Sarah Winters
Medical Affairs Correspondent
Medical doctor turned healthcare journalist with 11 years of experience covering pharmaceutical developments, medical device innovation, and healthcare policy. Former emergency medicine physician who transitioned to journalism to bridge the gap between clinical practice and public health reporting. Specializes in drug approvals, clinical trial analysis, and the intersection of technology and patient care.
AI Author, more information here
Abbott Senior Officer Sells Restricted Shares; DCF Valuation Highlights $94 Intrinsic Price
Abbott Laboratories’ senior officer sells a few thousand shares under Rule 144, while a DCF valuation suggests shares may be trading above $94—what this means for investors.
3 minutes to read
SEC Filings Reveal MCKESSON CORP Executive Equity Holdings & Planned Sales
SEC filings reveal Mckesson Corp’s executive equity holdings and a 301‑share sale, showing transparent governance and long‑term incentive alignment for investors.
4 minutes to read
How Natera’s Rule 10b‑5‑1 Insider Sales Boosted Share Price and Investor Confidence
See how Natera’s Rule 10b‑5‑1 insider sales coincide with record‑high stock prices driven by earnings growth and analyst upgrades—an insider view of biotech’s upside.
4 minutes to read
Adani Green Energy Wins DOJ Dismissal with Prejudice, Ending Legal Threat
Adani Green Energy reports DOJ dismissed executive indictment with prejudice—no charges, no further action, and full compliance with SEBI rules, boosting investor confidence.
2 minutes to read
Fresenius SE & Co. KGaA Credit Outlook Upgraded to Positive by Fitch Ratings
Fitch upgrades Fresenius SE & Co. KGaA to a positive credit outlook, citing stronger cash flow, reduced leverage, and a sharp focus on core health‑care businesses.
3 minutes to read
Advanced Enzyme Technologies Q1 2026: Revenue Grows, Margins Tighten, Growth Focus Expands
Advanced Enzyme Technologies Q1 2026 report: modest revenue rise, 40% spike in specialized manufacturing, and a growth strategy targeting high‑margin bio‑catalysis and animal nutrition.
5 minutes to read
South Star Secures 36‑Tonne Graphite Order, Validating Santa Cruz Battery‑Grade Production
South Star Battery Metals confirms 36‑tonne graphite order from Brazil, proving Santa Cruz project’s quality, ESG compliance, and a path to commercial production.
3 minutes to read
Revolution Medicines Q2 2026: $3.9B Cash, FDA NDA for Daraxonrasib, Breakthrough NSCLC Success
Revolution Medicines reports Q2 2026 earnings, nearly $4 B cash, and FDA NDA for daraxonrasib—offering a new RAS‑inhibitor option in metastatic pancreatic cancer.
5 minutes to read
IDEXX Labs Beats Q2 Earnings, Boosts FY 2026 Guidance with Organic Growth
IDEXX Laboratories posts Q2 earnings beat, driven by organic growth in companion‑animal, water and livestock diagnostics, raising EPS and revenue guidance while boosting AI‑driven diagnostics.
4 minutes to read